Trader consensus on Polymarket leans slightly toward "No" at 55% implied probability for a CDC Level 3 Travel Health Notice—signifying "Reconsider Nonessential Travel" for any disease—by December 31, 2026, driven by the absence of sustained human-to-human transmission in monitored threats. Official CDC surveillance confirms no active Level 3 notices, with highest alerts at Level 2 for chikungunya outbreaks in multiple regions, global polio circulation, and clade II mpox in Ghana and Liberia; global measles stays at Level 1 despite nearly 1,800 U.S. cases year-to-date. Recent FluView reports through week 16 show no new H5N1 avian influenza human infections or unusual activity. Escalation risks persist with summer travel boosting measles spread, but baseline epidemiology favors stability; watch weekly CDC updates for shifts.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日はい
$115,735 Vol.
$115,735 Vol.
2026/12/31
はい
$115,735 Vol.
$115,735 Vol.
2026/12/31
This market will resolve to "Yes" if the CDC issues a Level 3 (“Reconsider Nonessential Travel”) Travel Health Notice for any disease by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A Level 3 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.Trader consensus on Polymarket leans slightly toward "No" at 55% implied probability for a CDC Level 3 Travel Health Notice—signifying "Reconsider Nonessential Travel" for any disease—by December 31, 2026, driven by the absence of sustained human-to-human transmission in monitored threats. Official CDC surveillance confirms no active Level 3 notices, with highest alerts at Level 2 for chikungunya outbreaks in multiple regions, global polio circulation, and clade II mpox in Ghana and Liberia; global measles stays at Level 1 despite nearly 1,800 U.S. cases year-to-date. Recent FluView reports through week 16 show no new H5N1 avian influenza human infections or unusual activity. Escalation risks persist with summer travel boosting measles spread, but baseline epidemiology favors stability; watch weekly CDC updates for shifts.
This market will resolve to "Yes" if the CDC issues a Level 3 (“Reconsider Nonessential Travel”) Travel Health Notice for any disease by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A Level 3 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.
A Level 3 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.
マーケット開始日： Jan 19, 2026, 3:15 PM ET
音量
$115,735終了日
2026/12/31マーケット開始日
Jan 19, 2026, 3:15 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if the CDC issues a Level 3 (“Reconsider Nonessential Travel”) Travel Health Notice for any disease by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A Level 3 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.Trader consensus on Polymarket leans slightly toward "No" at 55% implied probability for a CDC Level 3 Travel Health Notice—signifying "Reconsider Nonessential Travel" for any disease—by December 31, 2026, driven by the absence of sustained human-to-human transmission in monitored threats. Official CDC surveillance confirms no active Level 3 notices, with highest alerts at Level 2 for chikungunya outbreaks in multiple regions, global polio circulation, and clade II mpox in Ghana and Liberia; global measles stays at Level 1 despite nearly 1,800 U.S. cases year-to-date. Recent FluView reports through week 16 show no new H5N1 avian influenza human infections or unusual activity. Escalation risks persist with summer travel boosting measles spread, but baseline epidemiology favors stability; watch weekly CDC updates for shifts.
This market will resolve to "Yes" if the CDC issues a Level 3 (“Reconsider Nonessential Travel”) Travel Health Notice for any disease by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A Level 3 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.
A Level 3 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.
音量
$115,735終了日
2026/12/31マーケット開始日
Jan 19, 2026, 3:15 PM ETResolver
0x65070BE91...Trader consensus on Polymarket leans slightly toward "No" at 55% implied probability for a CDC Level 3 Travel Health Notice—signifying "Reconsider Nonessential Travel" for any disease—by December 31, 2026, driven by the absence of sustained human-to-human transmission in monitored threats. Official CDC surveillance confirms no active Level 3 notices, with highest alerts at Level 2 for chikungunya outbreaks in multiple regions, global polio circulation, and clade II mpox in Ghana and Liberia; global measles stays at Level 1 despite nearly 1,800 U.S. cases year-to-date. Recent FluView reports through week 16 show no new H5N1 avian influenza human infections or unusual activity. Escalation risks persist with summer travel boosting measles spread, but baseline epidemiology favors stability; watch weekly CDC updates for shifts.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日
外部リンクに注意してください。
外部リンクに注意してください。
よくある質問